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Abstract There are several reports on cardiac adverse 
reactions attributed to the antimigraine drug sumatrip- 
tan in the recent literature. In order to assess the fre- 
quency and the character of adverse reactions to suma- 
triptan, a postmarketing cohort study was performed 
one year after registration of the drug in The Nether- 
lands. 
With assistance of86 % of the drug dispensing ener- 
al practitioners in The Netherlands, 1727 patients who 
had received sumatriptan were traced in July, 1992. Via 
their general practitioners, a questionnaire about use of 
sumatriptan, adverse reactions and other medication 
was sent to the patients in December 1992. During the 
study period, seven patients were lost to follow-up. Of 
the 1720 remaining patients, 1202 (70 %) responded to 
the questionnaire, of whom 1187 had actually used su- 
matriptan. 
The most frequently reported suspected adverse re- 
actions were paraesthesiae (139patients, 95% CI 
9.9%-13.5 %) and dizziness (96 patients, 95% CI 
6.5 %-9.7 %). Chest pain after use of sumatriptan was 
reported by 94 patients (7.9 %, 95 % CI 6.4 %-9.4 %), 
and according to the close temporal relationship with 
the intake of sumatriptan and a positive rechallenge, a 
causal relationship was probable in most of those pa- 
tients. The frequency of chest pain attributed to suma- 
triptan was higher in females (9.0 % vs 4.6 %; relative 
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risk 1.9, 95 % CI 1.1-3.4). Age and hypertension were 
not associated with chest pain attributed to sumatrip- 
tan. Dyspnoea ttributed to sumatriptan was reported 
by 26 patients (2.2 %), and was associated with obstruc- 
tive lung disease (relative risk 5.4 95 % CI 1.7-16.9). 
Thus, in view of the high frequency of chest pain after 
use of sumatriptan and reports in the literature of cardi- 
ac disturbances, including myocardial infarction, cau- 
tious use of the drug is advised. 
Keywords Sumatriptan, Migraine; pharmacoepide- 
miology, adverse reaction, angina pectoris, postmarket- 
ing surveillance, general practitioner 
The serotonin-1 (5HT-1) agonist sumatriptan is a new 
anti-migraine drug, which has been registered in sever- 
al European countries and recently in the United 
States, too [1]. It has been demonstrated that sumatrip- 
tan is highly effective, rapidly acting and well-tolerated 
in the treatment of acute attacks of migraine [2]. Mi- 
graine is a common eurological disorder [3], that can 
severely affect quality of life and daily function. 
In May 1991, sumatriptan was registered inThe Neth- 
erlands for the treatment of acute attacks of migraine 
and cluster headache. However, shortly after marketing 
of the drug, The Netherlands Centre for Monitoring of 
Adverse Reactions to Drugs received several reports of 
typical attacks of angina pectoris after use of sumatrip- 
tan [4]. The occurrence of these drug-related symptoms 
was confirmed by other investigators [5]. Reports from 
several clinical trials did not mention chest symptoms 
after use of sumatriptan [2, 6, 7]. Other authors estimat- 
ed the frequency of the experience ofsensations ofpres- 
sure and tightness in the chest at 3 % to 5 % of patients 
treated with sumatriptan [8]. Since no electrocardio- 
graphic (ECG) evidence of cardiac ischaemia had been 
demonstrated in the clinical trials, the mechanism of 
these complaints remained unclear. However, after mar- 
keting of the drug, two patients were reported who de- 
veloped chest pain, accompanied byserious ST abnorm- 
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Table 1 Characteristics of the study population 
Patients (%) 
(number) 
Males 284 (24) 
Females 918 (76) 
Mean age (years) 43 (11 a) 
Obstructive lung disease 28 (2,4) 
Hypertension 49 (4.1) 
Diabetes mellitus 4 (0.3) 
a Standard eviation 
alities in the ECG, after sumatriptan 6 mg SC [9, 10], a 
young female developed acute myocardial infarction 
after SC administration of sumatriptan [11], and two 
cases were reported of serious ventricular arrhythmias 
after its use [12]. Furthermore, two small angiographic 
studies demonstrated a significant reduction in coro- 
nary artery diameter in humans both after IVand SC ad- 
ministration of sumatriptan [13, 14]. 
The postmarketing experience with sumatriptan 
forced us to perform a pharmacoepidemiological study 
to gain more insight into the incidence and the charac- 
ter of the (cardiovascular) adverse reactions due to su- 
matriptan. 
Patients and methods 
Patients 
In July 1992, an enquiry was held involving all 687 drug dispensing 
general practitioners in The Netherlands. They were asked to pro- 
vide the date of birth and gender of every person to whom suma- 
triptan had been dispensed since it was marketed in May 1991. 
Subsequently, general practitioners who had dispensed sumatrip- 
tan were asked to send a questionnaire to be completed at home 
to the patients who had used sumatriptan. The questionnaires 
were sent via the general practitioners in prestamped envelopes 
with a standard letter from our Centre, In the questionnaire, the 
patients were asked whether they had indeed used sumatriptan, 
and if so, whether they had observed possible adverse reactions 
after it. They were also asked about he temporal relationship be- 
tween administration f sumatriptan and the observed adverse re- 
actions, and whether the possible adverse reactions recurred after 
rechallenge. Finally, they were asked whether they used other 
medication, and if so, what the indication was. To avoid bias, no ad- 
verse reactions were specified in the questionnaire, and the general 
practitioners were not informed about our particular interest in 
chest pain. Chest pain was defined as pain or pressure feelings, lo- 
cated substernally or in the chest. The enquiry was sent to the pa- 
tients in December 1992. The physicians none of whose patients 
had responded received a reminder in March 1993. Patients were 
classified as diabetic if they were taking anti-diabetic drug ther- 
apy, and as hypertensive if they were currently taking antihyper- 
tensive medication for the indication hypertension. Obstructive 
lung disease was assumed to be present if patients were using lung 
medication (mainly inhaled fi-adrenoceptor agonists and corticos- 
teroids) for one or more of the indications asthma, chronic bron- 
chitis or emphysema. 
Data analysis 
Differences between group means were tested by Student's t test. 
A Z 2 test was used to assess differences between proportions, with 
Fisher's exact est if there was an expected cell value of less than 
5.95 % confidence intervals of proportions were calculated on the 
basis of an assumed binomial distribution [15]. All calculated P va- 
lues are two-tailed. Statistical significance was defined as a two- 
sided P-value less than 0.05, Relative risks were calculated with 
95 % confidence intervals (95 % CI). 
Results 
The request  to the 687 drug dispensing eneral  pract i -  
t ioners y ie lded a response rate of 86 % (589 general  
pract i t ioners) .  Of  the 589 general  pract i t ioners,  474 had 
d ispensed sumatr ip tan  on at least one occasion to a to- 
tal of 1727 pat ients (24 % males, 76 % females).  Dur ing  
the study per iod,  seven pat ients  were lost to fol low up, 
all due to change of residence.  Of  the 1720 remain ing 
patients, 1202 (70 %) re turned the quest ionnaire.  
The basic character ist ics of this study popu lat ion  are 
summar ized  in Table 1. It compr ised 284 males with a 
mean age of 44 years and 918 females with a mean age 
of 43 years. F i f teen pat ients  (2 males, 13 females)  had 
not  yet  used sumatr iptan,  and were exc luded from fur- 
ther analyses. 
Table 2 Frequency of the most 
common adverse reactions 
(frequency >2 %) attributed to 
sumatriptan reported by 1187 
patients 
Some patients reported more 
than one adverse reaction 
Adverse reaction Patients Frequency (%) 95 % confidence interval 
Abdominal pain 31 (2.6) 1.7-3.5 
Chest pain 94 (7.9) 6.4-9.4 
Dizziness 96 (8.1) 6.5-9.7 
Drowsiness/sedation 83 (7.0) 5.5-8.5 
Dyspnoea 26 (2.2) 1.4-3.0 
Fatigue 54 (4.6) 3.4-5.8 
Feeling of heaviness 95 (8.0) 6.5-9.5 
Flushing 60 (5.1) 3.8-6.4 
Headache 37 (3.1) 2.1-4.1 
Injection site reaction 35 (3.0) 2.1-4.0 
Muscle pain 28 (2.4) 1.5-3.3 
Nausea and/or vomiting 87 (7.3) 5.8-8.8 
Palpitations 33 (2.8) 1.9-3.7 
Paraesthesiae 139 (11.7) 9.%13.5 
Pressure in throat 39 (3.3) 2.3-4.3 
The most commonly suspected adverse reactions re- 
ported by the 1187 patients who had taken sumatrip- 
tan, are shown in Table 2. The most frequent were para- 
esthesiae (139 patients, 11.7 %, 95 % CI 9.9 %-13.5 %) 
and dizziness (96 patients, 8.1%, 95 % CI 6.5 %-9.7 %). 
Chest pain after use of sumatriptan was reported by 
94 patients (7.9 %, 95 % CI 6.4 %-9.4 %) with a mean 
age of 41 y (range 19 to 69 y; not significantly different 
from the total study population). This subgroup com- 
prised 13 males (4.6 %) and 81 females (9.0 %), result- 
ing in a relative risk of females compared to males of 
1.9 (95 % CI 1.1-3.4). 81 of these patients (86 %) experi- 
enced chest pain within i h after administration of su- 
matriptan, and in 83 patients (88 %) the adverse reac- 
tion occurred more than once. Of the 94 patients who 
had experienced chest pain after use of sumatriptan, 
6 patients (6.4 %) had hypertension, a proportion that 
was not significantly different from the total study 
group. Dyspnoea after sumatriptan was reported by 
26 patients (2.2 %, 95 % CI 1.4 %-3.0 %), 21 women 
and 5 men, of average age 39 y. Of those 26 patients, 
24 patients (92%) experienced yspnoea within 1 h 
after administration of sumatriptan, and in 22 patients 
(85 %) the reaction recurred after rechallenge. Of the 
28 patients with obstructive lung disease, 3 patients ex- 
perienced yspnoea fter use of sumatriptan, as com- 
pared to 23 in the other patients, resulting in a relative 
risk of 5.4 (95 % CI 1.7-16.9). 
Discussion 
Postmarketing studies of adverse reactions to drugs can 
provide information not available from premarketing 
studies, mainly because the latter are limited in size 
and often exclude important subgroups of patients. 
One of the most worrying findings in our study was the 
high frequency of chest pain (7.9 %) after use of suma- 
triptan. The close temporal relationship between the in- 
take of sumatriptan and chest pain, and the recurrence 
of the same symptoms after renewed exposure (posi- 
tive rechallenge) in many patients makes a causal rela- 
tionship between the use of sumatriptan and chest pain 
probable in most of the patients. Another interesting ad- 
verse reaction was dyspnoea, as reported by 26 patients 
(2.2 %). 
To investigate adverse drug reactions via drug dis- 
pensing general practitioners, by sending a question- 
naire via them to the consumers of a specific drug in 
their practices, is a novel approach. Due to the strin- 
gent privacy regulations in The Netherlands [16], we 
could not send the questionnaires directly to the pa- 
tients, and instead we asked the general practitioners to 
do so. The 687 general practitioners with a drug dis- 
pensing outlet in The Netherlands encompass a catch- 
ment population of approximately 1,500,000 inhabi- 
tants (10% of the total population in The Nether- 
lands). For a physician-based study, 86 % cooperation is
remarkably high compared to other studies, e.g. those 
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in the United Kingdom [17], and offers the opportunity 
for future studies. The fact that the drug dispensing en- 
eral practitioners record both morbidity and drug dis- 
pensing, makes them a very useful source of informa- 
tion for studying ad hoc problems with newly marketed 
drugs. Although the catchment population of the drug 
dispensing eneral practitioners may not be representa- 
tive of the total population in every aspect, we think 
that it is representative of the determinants in our study. 
We did not include any reference group in our study 
for two reasons. First, we were mainly interested in ad- 
verse reactions with a close temporal relationship to 
the use of sumatriptan, and a relatively low background 
incidence in the middle-aged. As it is unlikely that many 
reference patients would have developed chest pain in 
the same short periods in which the index patients were 
exposed, a reference group was not deemed necessary. 
And second, as sumatriptan is contraindicated in pa- 
tients with angina pectoris and variant angina, such pa- 
tients might have been overrepresented in a reference 
group of patients with migraine. 
Assessment of the likelihood of a causal relationship 
between the intake of sumatriptan and certain reported 
reactions was difficult. Reactions such as nausea or 
headache might well have also been symptoms of the 
underlying disease, migraine or cluster headache. 
We have no direct data about the mechanism of the 
chest pain observed in our study group, but we cannot 
exclude a cardiac origin. It is possible that in some pa- 
tients the chest symptoms were caused by myocardial 
ischaemia, due to sumatriptan-induced coronary artery 
spasm. It is well known that coronary artery spasm can 
be induced by several drugs, including the antimigraine 
drugs ergotamine and methysergide [18-20]. Some evi- 
dence for this hypothesis with regard to sumatriptan 
can be found in the literature. Isolated human basilar ar- 
tery rings contracted in response to sumatriptan [21], as 
did normal and atherosclerotic human epicardial coro- 
nary artery rings from explanted hearts [22, 23]. 
Furthermore, two small studies of patients undergo- 
ing diagnostic oronary arteriography demonstrated a 
significant reduction in coronary artery diameter both 
after IV and SC administration of sumatriptan [13, 14]. 
Even during the early evaluation of sumatriptan, when 
it was administered IV, a case of possible myocardial 
ischaemia was recorded; the patient experienced chest 
symptoms accompanied by ST-segment elevation on 
electrocardiogram [8]. After marketing, several case re- 
ports of cardiac disturbances due to use of sumatriptan 
were published [9-12]. However, despite these indica- 
tions for a cardiac origin of the chest symptoms, we can- 
not exclude some other mechanism. In general, no car- 
diac abnormalities were identified in 10-30 % of the pa- 
tients with angina-like retrosternal chest pain [24], and 
oesophageal bnormalities were found in 30-60 % of 
these patients [25, 26]. 
The frequency of chest pain attributed to sumatriptan 
is remarkably high in our study. Although the response 
of 70 % of the patients to the questionnaire was high, 
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the 30 % of patients who did not respond to the ques- 
tionnaire might have influenced the results. However, 
even if the 516 non-responding patients did not include 
even one single case of chest pain attributable to suma- 
triptan, the incidence would have exceeded 5 %. It is sur- 
prising that in several studies, including one with a study 
group of more than 600 patients, chest pain due to suma- 
triptan was not reported [2, 6, 7]. Furthermore, the fre- 
quency of chest pain attributed to sumatriptan in our 
study is higher than in several clinical trials [27, 28], and 
in postmarketing studies based on reports from physi- 
cians [5, 29]. In trials, a low incidence may be explained 
by rigorous patient selection and the exclusion of sub- 
jects with a history of angina pectoris and variant angi- 
na. Our postmarketing study in patients gave a much 
higher figure of chest pain than our study based on data 
from general practitioners [29]. Apparently, cases of 
chest pain are easily missed unless the patient is specifi- 
cally asked about adverse reactions. It cannot be exclud- 
ed that in some patients in our study, chest pain was in- 
duced by concomitant use of ergot alkaloids. 
It is not yet clear whether the effects of the serotonin- 
1 agonist sumatriptan on coronary-artery dimensions 
differ between patients with and without coronary 
atherosclerosis. Serotonin itself has a vasodilating ef- 
fect on normal human coronary arteries, but when the 
endothelium is damaged, as in coronary artery disease, 
it has a direct, unopposed vasoconstricting effect [30], 
and in patients with variant angina it may cause occlu- 
sive coronary artery spasm [31]. It has been suggested 
that in patients with ischaemic heart disease, constric- 
tion of coronary arteries is mediated in particular by 5- 
HTl-l ike receptors [32]. Some clinical studies suggested 
a dose relationship with chest symptoms [33]. Another 
reason why the frequency of chest pain in our study 
was higher than has previously been reported, may be 
the fact that the present patients had taken sumatriptan 
on several occasions during the study period. The inves- 
tigation does not give any in sight into the incidence per 
administration of sumatriptan. 
Dyspnoea s an adverse reaction to sumatriptan has 
previously been reported [5], but the relationship with 
asthma has been disputed [34]. We considered chronic 
use of lung medication for one or more of the indica- 
tions asthma, chronic bronchitis or emphysema as a reli- 
able marker of current obstructive lung disease. An as- 
sociation between dyspnoea ttributed to sumatriptan 
and obstructive lung disease was demonstrated here. 
The mechanism of this adverse reaction is unclear, but 
an increase both in pulmonary arterial pressure and pul- 
monary wedge pressure due to sumatriptan have been 
demonstrated [13, 14]. Furthermore, serotonin itself is 
a bronchoconstrictor, although this para-sympathetic ef- 
fect is mediated by stimulation of 5-HTz receptors [35]. 
It is not clear, however, whether the dyspnoea in our pa- 
tients was due to pulmonary congestion, bronchospasm 
or another mechanism. 
Based on the results of this study, and other post- 
marketing reports, we advise cautious use of sumatrip- 
tan, in particular in patients who experience chest pain 
after its use. In our opinion, every patient with chest 
pain suggestive of angina pectoris, drug-induced or not, 
requires careful evaluation, including a history, physical 
examination, electrocardiogram, and simple laboratory 
tests [36]. We recommend further investigation of the 
mechanism of the chest symptoms attributed to suma- 
triptan. It may be useful to assess risk factors for the de- 
velopment of chest pain due to sumatriptan. Finally, we 
conclude that sending questionnaires to patients via 
their (drug dispensing) general practitioner is a very 
useful source of information for studying ad hoc pro- 
blems due to newly marketed rugs. 
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